Please login to the form below

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari
FDA clears Alnylam’s second RNAi drug for rare disease

Alnylam was also responsible for the first – Onpattro (patisiran) – which was launched for rare disease hereditary ATTR amyloidosis last year with a $450, 000 per year price tag, dropping to $345,
Alnylam gains key NICE approval for Onpattro

Patisiran has shown in its main clinical study that it can halt or even improve potentially debilitating symptoms of this disease in the majority of patients.

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

How early-stage clinical research is facilitating the new wave of personalised medicines

The first ever siRNA therapy was only approved by the US Food and Drug Administration (FDA) in 2018 – Patisiran for the treatment of the nerve disease (polyneuropathy) – and two further siRNA
20 for 2020 – Five pharma leaders to watch in 2020

So far, its first launch Onpattro (patisiran) has been growing pretty slowly.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Its pivotal APOLLO trial showed nearly all patisiran-treated patients saw the disease halted or slowed, with more than half seeing their neuropathy reversed.
Deal Watch table for January 2014

Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
Pharma deals during January 2014

The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Group Account Director, Patient focussed account, Healthcare com...: circa £90K

Digital Engagement Strategist, Healthcare Brand Communications, ...: £75-90K

Project Director, Healthcare Marketing Agency patient focus Lond...: Highly competitive salary

Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...: Highly competitive salary

Digital Project Director, Healthcare Marketing Agency patient fo...: Highly competitive salary

Senior Medical Writer/ Copywriter, Flexible Location, Flexible D...: Salary TBC

Senior Consultant, Pricing & Market Access Consultancy, circ...: circa £100K package

Add my company

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Ask the writers: Transitioning from academia to medical writing: Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset: By James Aird...
Guide: How to embrace behavioural science principles in healthcare MR...

Email:
Password: